Dr Attard is a Cancer Research UK clinician scientist and consultant medical oncologist at The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London in 2010. His main research interest is the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and has led on the early clinical development of abiraterone acetate, a novel inhibitor of CYP17. He is a co-author of more than 70 peer-reviewed manuscripts and has published several important papers on advanced prostate cancer. He also sits on a number of advisory boards.Dr. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. He devotes the majority of his time to academic research, both in the laboratory, investigating novel therapies for the treatment of prostate cancer, and in clinical trial research.

 Oncology